Redhill Biopharma Ltd (NASDAQ:RDHL) — Market Cap & Net Worth

$3.34 Million USD · Rank #29386

Market Cap & Net Worth: Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd (NASDAQ:RDHL) has a market capitalization of $3.34 Million ($3.34 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29386 globally and #6002 in its home market, demonstrating a -15.38% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Redhill Biopharma Ltd's stock price $0.55 by its total outstanding shares 6080920 (6.08 Million). Also see balance sheet size of Redhill Biopharma Ltd for a full breakdown of the balance sheet.

Redhill Biopharma Ltd Market Cap History: 2015 to 2026

Redhill Biopharma Ltd's market capitalization history from 2015 to 2026. Data shows change from $78.32 Billion to $3.34 Million (-60.36% CAGR). Also see how efficiently does Redhill Biopharma Ltd generate cash for how efficiently the company converts equity into cash flow.

Index Memberships

Redhill Biopharma Ltd is a constituent of 2 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
NASDAQ Health Care IXHC	$2.66 Trillion	0.00%	#855 of 976
NASDAQ Composite IXIC	$41.69 Trillion	0.00%	#2736 of 3165

Weight: Redhill Biopharma Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Redhill Biopharma Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Redhill Biopharma Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Redhill Biopharma Ltd stock quote for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

21.90x

Redhill Biopharma Ltd's market cap is 21.90 times its annual revenue

Industry average: 0.57x Higher than industry average

Latest Price to Earnings (P/E) Ratio

N/A

P/E ratio not applicable due to negative or zero earnings

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$63.61 Billion	$101.00K	-$29.37 Million	629766.57x	N/A
2017	$31.26 Billion	$4.01 Million	-$45.54 Million	7800.33x	N/A
2018	$33.75 Billion	$8.36 Million	-$38.82 Million	4036.97x	N/A
2019	$36.91 Billion	$6.29 Million	-$42.30 Million	5867.30x	N/A
2020	$49.13 Billion	$64.36 Million	-$76.17 Million	763.43x	N/A
2021	$15.69 Billion	$85.76 Million	-$97.74 Million	182.94x	N/A
2022	$853.15 Million	$61.80 Million	-$71.67 Million	13.81x	N/A
2023	$221.95 Million	$6.53 Million	$23.92 Million	33.99x	9.28x
2024	$37.76 Million	$8.04 Million	-$8.27 Million	4.70x	N/A
2025	$6.26 Million	$286.00K	-$429.00K	21.90x	N/A

Competitor Companies of RDHL by Market Capitalization

Companies near Redhill Biopharma Ltd in the global market cap rankings as of September 18, 2026. Review Redhill Biopharma Ltd (RDHL) tangible net worth to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Redhill Biopharma Ltd by market ranking:

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#519	Takeda Pharmaceutical Co Ltd ADR	NYSE:TAK	$52.60 Billion	$16.65
#633	Takeda Pharmaceutical Company Limited	F:TKDA	$43.60 Billion	€16.00
#640	GALDERMA GROUP AG	NYSE:GALDY	$43.16 Billion	$37.02
#670	Jiangsu Hengrui Medicine Co Ltd	SHG:600276	$40.62 Billion	CN¥43.52

Redhill Biopharma Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, Redhill Biopharma Ltd's market cap moved from $78.32 Billion to $ 3.34 Million, with a yearly change of -60.36%.

Year	Market Cap	Change (%)
2026	$3.34 Million	-46.60%
2025	$6.26 Million	-83.41%
2024	$37.76 Million	-82.99%
2023	$221.95 Million	-73.98%
2022	$853.15 Million	-94.56%
2021	$15.69 Billion	-68.07%
2020	$49.13 Billion	+33.11%
2019	$36.91 Billion	+9.37%
2018	$33.75 Billion	+7.98%
2017	$31.26 Billion	-50.86%
2016	$63.61 Billion	-18.79%
2015	$78.32 Billion	--

End of Day Market Cap According to Different Sources

On Sep 17th, 2026 the market cap of Redhill Biopharma Ltd was reported to be:

Source	Market Cap
Yahoo Finance	$3.34 Million USD
MoneyControl	$3.34 Million USD
MarketWatch	$3.34 Million USD
marketcap.company	$3.34 Million USD
Reuters	$3.34 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Redhill Biopharma Ltd

NASDAQ:RDHL USA Drug Manufacturers - Specialty & Generic

Market Cap

$3.34 Million

Market Cap Rank

#29386 Global

#6002 in USA

Share Price

$0.55

Change (1 day)

-4.36%

52-Week Range

$0.55 - $2.52

All Time High

$16290.00